BFRI BIOFRONTERA INC

Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Woburn, MA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025.

Company Webcast

The webcast presentation will take place at 1:15 p.m. ET on Tuesday, September 30, 2025. The webcast can be accessed by visiting the conference home page at or directly at . The webcast will also be available for replay following the event.

1x1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at or register for the event at .

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit and follow Biofrontera on and .

Investor Relations Contact

Ben Shamsian

Lytham Partners

646-829-9701



EN
26/09/2025

Underlying

BFRIBIOFRONTERA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOFRONTERA INC

 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

U.S. Patent Office Issues Final Written Decision Finding All Challenge...

U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”), today announced that on February 23, 2026, the U.S. Patent Trial and Appeal Board (the “Board”) issued a Final Written Decision finding all challenged claims of Sun Pharmaceutical Industries, Inc.’s U.S. Patent No. 11,697,028 (the “’028 Patent”) to be unpatentable. ...

8h / 50m 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics S...

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities Phase 1 maximal-use pharmacokinetics (PK) study completed in support of planned U.S. label expansionData to complement previously announced positive Phase 3 efficacy results on extremities, neck and trunkSupplemental NDA submission for extremities, neck and trunk indication expected in Q3 2026 WOBURN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the dev...

February 17, 2026 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug A...

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz® would be the first and only PDT photosensitizer indicated for the treatment of superficial Basal Cell Carcinoma (sBCC) in the USBCC is the most common skin cancer in the US with 3.6 million cases diagnosed annually1 WOBURN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical compa...

February 11, 2026 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT...

Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint Study findings met its primary endpoint and showed highly statistically significant superiority for Ameluz® vs. vehicle gel (p

February 9, 2026 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Reve...

Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth Fourth quarter results represent highest quarterly revenue in Company’s historyQ4 year-over-year growth of 35% to 39% driven by sales execution of Ameluz®Full year 2025 revenues also expected to show double-digit growth of 11% to 13% WOBURN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a leader in photodynamic therapy (PDT) development and commercialization, to...

January 13, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch